HAL (France)open access
Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting
Pharmaceutical, Health policy, Economics, Neoplasms, 0, Costs and cost analysis, Patient preference, Biosimilar pharmaceuticals
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 677221
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.